Maxcyte (MXCT) Change in Receivables (2020 - 2026)

Maxcyte (MXCT) has 7 years of Change in Receivables data on file, last reported at $743000.0 in Q1 2026.

• On a quarterly basis, Change in Receivables fell 11.44% year-over-year to $743000.0 in Q1 2026; TTM through Mar 2026 was -$1.2 million, a 70.41% decrease from a year earlier, with the FY2025 full-year figure at -$1.1 million, up 6.36% from the prior year.
• Change in Receivables for Q1 2026 stood at $743000.0, up from -$4.8 million in the prior quarter.
• Over the last five years, Change in Receivables for MXCT reached as high as $4.0 million in Q4 2022 and fell as low as -$4.8 million in Q4 2025.
• Historically, Change in Receivables has averaged -$134588.2 across 5 years, with a median of $122000.0 in 2024.
• Across the five-year window, Change in Receivables surged 46455.56% in 2023 and sank 4031.97% in 2025, its largest moves.
• Year by year, Change in Receivables stood at $4.0 million in 2022, then sank by 141.25% to -$1.7 million in 2023, then surged by 107.37% to $122000.0 in 2024, then sank by 4031.97% to -$4.8 million in 2025, then jumped by 115.49% to $743000.0 in 2026.
• Per Business Quant data, the three most recent Change in Receivables figures were $743000.0 in Q1 2026, -$4.8 million in Q4 2025, and $2.6 million in Q3 2025.